BD announced Canadian Government order of 76 million portable, rapid point-of-care antigen tests to detect SARS-CoV-2
On Nov. 10, 2020, BD (Becton, Dickinson) announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the…
-
-
Data showed SARS-CoV-2 reactive T Cells are associated with protection from COVID-19 was published
On Nov. 10, 2020, Oxford Immunotec announced the release of data from a prospective cohort study in keyworkers…
-
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
On Nov. 9, 2020, a National Institutes of Health (NIH) clinical trial evaluating the safety and effectiveness of…
-
Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19
On Nov. 9, 2020, a study published in JAMA reported the effect of hydroxychloroquine on clinical status at…
-
Lilly’s neutralizing antibody bamlanivimab received FDA emergency use authorization for treatment of recently diagnosed COVID-19
On Nov. 9, 2020, the FDA granted Emergency Use Authorization (EUA) for Eli Lilly’s investigational neutralizing antibody bamlanivimab…
-
Pfizer and BioNTech announced vaccine candidate against COVID-19 achieved success in interim analysis from phase 3 study
On Nov. 9, 2020, Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence…
-
Corvus completed enrollment in phase 1 study of CPI-006 for patients with COVID-19
On Nov. 9, 2020, Corvus Pharmaceuticals announced that it had completed patient enrollment in its Phase 1 study…
-
Fred Hutch began experimental COVID-19 vaccine efficacy trial
On Nov. 9, 2020, the Fred Hutchinson Cancer Research Center announced the start of volunteer enrollment for a…
-
White-tailed deer found to be huge reservoir of SARS-CoV-2 infection
On Nov. 8, 2020, research from the U.S. had shown that white-tailed deer were being infected with SARS-CoV-2,…
-
ImmunityBioﾒs hAd5 COVID-19 vaccine candidate stimulated memory T-Cell recall in patients with SARS-CoV-2
On Nov. 8, 2020, ImmunityBio announced positive study results for their human Ad5 (hAd5) COVID-19 vaccine candidate, which…
-
Humanigen announced CRADA agreement with U.S. government to develop lenzilumab for COVID-19
On Nov. 6, 2020, Humanigen announced that it had entered into a Cooperative Research and Development Agreement (CRADA)…
-
Novartis’ randomized, double-blind, placebo-controlled CAN-COVID trial failed to meet endpoints
On Nov. 5, 2020, Novartis announced data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial…
-
Relief Therapeutics and NeuroRx announced continuation of RLF-100ﾙ trial for treatment of COVID-19 respiratory failure
On Nov. 5, 2020, RELIEF THERAPEUTICS and NeuroRx announced that the independent Data Monitoring Committee (DMC) voted unanimously…
-
RECOVERY trial DMC recommended continuing evaluation of REGN-COV2 in hospitalized patients
On Nov. 5, 2020, Regeneron announced an update from the independent data monitoring committee (DMC) for the UK-based…
-
Neoleukin Therapeutics announced publication of de novo protein decoys that block COVID-19 infection
On Nov. 5, 2020, Neoleukin Therapeutics announced the publication in Science of research describing novel molecules designed to…
-
Mateon’s C001- A Global phase 2 study for OT-101 against COVID-19 received cleareence for patient enrollment
On Nov. 4, 2020, Mateon Therapeutics announced the receipt of approval from Instituto Nacional de Salud (INS), the…
-
Humanigen announced positive interim phase 3 data of lenzilumabﾙ in patients hospitalized with COVID-19
On Nov. 4, 2020, Humanigen announced positive interim Phase 3 data of lenzilumab in patients hospitalized with COVID-19….
-
Novavax and Commonwealth of Australia announced agreement for acquisition of Novavax COVID-19 vaccine
On Nov. 4, 2020, Novavax announced the signing of a non-binding Heads of Terms document with the Australian…
-
Stanford developed CRISPR ‘lab on a chip’ for detecting COVID-19
On Nov. 4, 2020, using the cutting-edge genetic editing technique known as CRISP ‘lab on a chip’ technology,…
-
Rapid COVID-19 test, Oxsed RaViD Direct, used at Heathrow and trials at Hong Kong International Airport
On Nov. 4, 2020, the University of Oxford announced that its rapid COVID-19 test was being used at…
-
Humanigen executed licensing agreement for Lenzilumab in COVID-19 for South Korea and the Philippines
On Nov. 3, 2020, Humanigen announced the execution of its first licensing transaction in the Asia-Pacific Region with…
-
OraSure’s DNA Genotek subsidiary received FDA EUA for its ORAcollect-RNA saliva collection device for SARS CoV-2
On Nov. 3, 2020, OraSure Technologies announced its DNA Genotek subsidiary has received Emergency Use Authorization from the…
-
Novavax announced facility expansion to support global vaccine development
On Nov. 2, 2020, Novavax announced the expansion of its Maryland campus to accommodate the company’s rapid growth…
-
Innovation Pharmaceuticals received pre-IND response from FDA on COVID-19 trial
On Nov. 2, 2020, Innovation Pharma announced receipt of written feedback from the FDA that is in general…
-
Immunic announced 200 patients enrolled in phase 2 CALVID-1 trial of IMU-838 for treatment of COVID-19
On Nov. 2, 2020, Immunic announced that the company had enrolled and randomized 200 patients, pre-specified in the…
-
ACON Laboratories announced the launch of its Flowflexﾙ Antigen COVID-19 test
On Nov. 2, 2020, ACON Laboratories announced the launch of its Flowflexﾙ SARS-COV-2 Antigen Rapid Test. The Flowflex…
-
Patriot Express Travel at BWI, SEATAC required on-site, rapid COVID-19 testing
On Nov. 1, 2020, the U.S. Department of Defense announced the start of rapid, on-site COVID-19 testing for…
-
InBios awarded $12.7M to boost production of two COVID-19 diagnostics
On Oct. 31, 2020, the U.S. Department of Health and Human Services and the U.S. Department of Defense…
-
389,000 BinaxNOW COVID-19 tests distributed to historically black colleges and universities
On Oct. 31, 2020, the U.S. Department of Health and Human Services (HHS) announced that 389,040 state-of-the-art Abbott…
-
Humanigen announced first patient dosed in phase 3 clinical study of Lenzilumab in COVID-19
On Oct. 30, 2020, Humanigen announced that MedStar Washington Hospital Center in Washington, D.C. treated its first COVID-19…
